MMS Shortlisted for Best CRO – Specialist Provider by the 2026 Scrip Awards
CANTON, Mich., and BELFAST, UK, September 29, 2026 – MMS, a leading data-focused global contract research organization (CRO), today announced it has been shortlisted in the Best Contract Research Organization (CRO) – Specialist Providers category by the 2026 Scrip Awards, recognizing the company’s excellence in delivering specialized clinical development, regulatory, biometrics, and data science solutions to pharmaceutical and biotechnology sponsors worldwide. The recognition highlights MMS’ continued commitment to helping sponsors navigate increasingly complex drug development challenges through scientific rigor, regulatory expertise, and technology-enabled innovation.
The Scrip Awards recognize organizations that demonstrate outstanding performance, innovation, and impact across the life sciences industry. The Best CRO – Specialist Providers category honors CROs that deliver focused, high-value services, helping sponsors accelerate development timelines, enhance decision-making, and achieve successful regulatory and clinical outcomes.
“For 20 years, MMS has remained focused on one goal: helping sponsors bring therapies to patients faster through innovative thinking and data-driven decision-making,” said Uma Sharma, CEO of MMS. “Being shortlisted for this award reflects the dedication of our global team and the trust our clients place in us to support some of the industry’s most challenging and high-priority development programs.”
Over the past year, MMS has continued to expand its impact across accelerated regulatory pathways, oncology, rare diseases, emerging therapeutic areas, and global submission programs. The company has supported critical regulatory milestones, while helping sponsors navigate novel regulatory considerations in rapidly evolving areas such as psychedelic-assisted therapies. MMS has supported more than 50 marketing applications over the past five years across major health authorities, including the FDA and EMA. Through its global biometrics and biostatistics expertise, MMS has also helped clients manage increasingly complex clinical data, strengthen evidence generation, and make more informed development decisions.
To help sponsors manage increasingly complex clinical development programs, MMS combines specialist expertise with technology-enabled solutions. The company’s proprietary platforms, Datacise® and KerusCloud®, provide sponsors with advanced analytics, trial simulation, data visualization, risk monitoring, and real-time insights that improve study oversight and support more informed development decisions. Together, these technologies help sponsors generate stronger evidence, optimize trial design, and enhance submission readiness.
“The industry’s most complex development challenges require a partner that combines strategic thinking, scientific excellence, and innovative technology,” said Ben Dudley, President and Chief Commercial Officer at MMS. “We are honored to be recognized alongside other leading organizations and remain committed to delivering the expertise, quality, and partnership our clients rely on.”
Winners of the 2026 Scrip Awards will be announced at an awards ceremony in London in December.
About MMS
MMS is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical, biotechnology, and medical device industries with a comprehensive suite of services spanning regulatory strategy, medical writing, biometrics, data science, regulatory operations, and submissions. For 20 years, MMS has helped sponsors solve complex development challenges through scientific rigor, innovative technology, and collaborative partnerships that accelerate the delivery of therapies to patients worldwide.